Literature DB >> 15239128

Peroxiredoxins, a novel protein family in lung cancer.

Siri T Lehtonen1, Anne-Mari Svensk, Ylermi Soini, Paavo Pääkkö, Pasi Hirvikoski, Sang Won Kang, Marjaana Säily, Vuokko L Kinnula.   

Abstract

Cigarette smoke, the major risk factor for lung cancer, induces an accumulation of reactive oxygen species. These have multiple effects on cell defense, cell proliferation and cell death. Thus, compounds involved in the regulators of redox balance can be hypothesized to play a fundamental role in both carcinogenesis and tumor progression. Here, we have evaluated the expressions of all 6 peroxiredoxins (Prxs I-VI) in lung carcinomas. Prxs represent a protein family with the capability of breaking down hydrogen peroxide; thus, they can participate in cellular antioxidant defense, regulate cell proliferation and increase drug resistance of cultured cells. Altogether 92 cases were investigated by immunohistochemistry, including 32 adenocarcinomas, 45 squamous cell, 9 small cell and 6 other carcinomas. Additionally, 11 cases with adenocarcinoma or squamous cell carcinoma were studied by Western analysis and/or by RT-PCR. Prxs I, II, IV and VI were particularly elevated in lung carcinomas as assessed by immunohistochemistry and/or RT-PCR. Western analysis revealed that Prxs I and IV were significantly elevated in tumors compared to nonmalignant tissue (p = 0.04 and 0.002, respectively). There were remarkable variations in Prx expression in various tumor subtypes, the most striking being Prx IV expression, which was mainly associated with adenocarcinoma. Elevated Prx VI expression was associated with high-grade squamous cell carcinoma (p = 0.03) and Prx II expression, with advanced tumor stage (p = 0.01). Our results suggest that Prxs may have effects on the progression of lung cancer. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239128     DOI: 10.1002/ijc.20294

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  54 in total

Review 1.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

3.  Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.

Authors:  Chul-Kee Park; Jin Hyun Kim; Min Jeong Moon; Ji Hye Jung; Su-Young Lim; Sung-Hye Park; Jong-Hoon Kim; Dong Gyu Kim; Hee-Won Jung; Byung-Kyu Cho; Sun Ha Paek
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-26       Impact factor: 4.553

4.  Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins.

Authors:  Rui Tian; Li-Ming Wei; Ren-Yi Qin; Yan Li; Zhi-Yong Du; Wei Xia; Cheng-Jian Shi; Hong Jin
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

5.  Downregulation of peroxiredoxin II suppresses the proliferation and metastasis of gastric cancer cells.

Authors:  Linjun Niu; Ang Liu; Wei Xu; Liang Yang; Wugang Zhu; Yuming Gu
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

Review 6.  Overview of peroxiredoxins in oxidant defense and redox regulation.

Authors:  Leslie B Poole; Andrea Hall; Kimberly J Nelson
Journal:  Curr Protoc Toxicol       Date:  2011-08

Review 7.  The Pursuit of Noninvasive Diagnosis of Lung Cancer.

Authors:  Thomas Atwater; Christine M Cook; Pierre P Massion
Journal:  Semin Respir Crit Care Med       Date:  2016-10-12       Impact factor: 3.119

Review 8.  Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase A₂ activities.

Authors:  Aron B Fisher
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

9.  Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients.

Authors:  Leonardo Lisbôa da Motta; Carolina B Müller; Marco A De Bastiani; Guilherme A Behr; Fernanda S França; Ricardo F da Rocha; Juliane B Minotto; Rosalva T Meurer; Marilda C Fernandes; Adriana Roehe; Melissa M Markoski; Cristiano F Andrade; Mauro A A Castro; Fábio Klamt
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-22       Impact factor: 4.553

10.  Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors.

Authors:  Sally Järvelä; Immo Rantala; Alejandra Rodriguez; Heini Kallio; Seppo Parkkila; Vuokko L Kinnula; Ylermi Soini; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.